Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes

Hepatology

Volumn 62, Issue 2, 2015, Pages 355-364

  Innes, Hamish A ^a,b   Mcdonald, Scott A ^a,b   Dillon, John F ^c   Allen, Sam ^d   Hayes, Peter C ^e   Goldberg, David ^a,b   Mills, Peter R ^f   Barclay, Stephen T ^g   Wilks, David ^h   Valerio, Heather ^a,b   Fox, Ray ⁱ   Bhattacharyya, Diptendu ^j   Kennedy, Nicholas ^k   Morris, Judith ^l   Fraser, Andrew ^m   Stanley, Adrian J ^g   Bramley, Peter ⁿ   Hutchinson, Sharon J ^a,b  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d CROSSHOUSE HOSPITAL   (United Kingdom)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^f GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ Brownlee Centre   (United Kingdom)

^j Kirkcaldy Hospital   (United Kingdom)

^k MONKLANDS HOSPITAL   (United Kingdom)

^l SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^m ABERDEEN ROYAL INFIRMARY   (United Kingdom)

ⁿ Stirling Royal Infirmary   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ANTIVIRUS AGENT;

ADULT; ALCOHOL INTOXICATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INTOXICATION; FEMALE; FOLLOW UP; HEPATITIS C; HOSPITALIZATION; HUMAN; LIFESTYLE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK REDUCTION; VIOLENCE; AGED; DISEASE COURSE; DRUG EFFECTS; FACTUAL DATABASE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER FAILURE; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SURVIVAL; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; CAUSE OF DEATH; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84938073591     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27766     Document Type: Article

References (36)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35-S46.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
3. Trembling P, Tanwar S, Rosenberg W, Dusheiko G. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:713-728.
4. Flemming TR, Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
5. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
6. Berenguer J, Rodriguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfecte with HIV and hepatitis C virus. Clin Infec Dis 2012;55:728-736.
7. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-516.
8. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014;59:1293-1302.
9. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-727.
10. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-744.
11. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 2014;59:1246-1249.
12. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011;54:1547-1558.
13. Akl EA, Oxman AD, Herrin J, Vist GE, Terrenato I, Sperati F, et al. Using alternative statistical formats for presenting risk and risk reductions. Cochrane Database Sust Rev 2011;16:CD006776.
14. Barratt A, Wyer PC, Hatala R, McGinn T, Dans AL, Keitz S, et al. Evidence-based medicine Teaching Tips Working Group: tips for learners of evidence-based medicine: 1. Relative risk reduction, absoluste risk reduction and number needed to treat. CMAJ 2004;171:353-358.
15. Scottish National Health Databases. SMR-01: http://www.adls.ac.uk/nhs-scotland/general-acute-inpatient-day-case-smr01/?detail; SMR-04: http://www.adls.ac.uk/nhs-scotland/smr04-mental-health-inpatient-and-day-case-dataset/?detail; CHI database: http://www.scot-ship.ac.uk/overview.html. All accessed April 2014.
16. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
17. Korcha R, Cheryl C, Witbrodt J, Borges G, Hejazi-Bazargan S, Bond J, et al. Violence-related injury and gender: the role of alcohol and alcohol combined with illict drugs. Drug Alcohol Rev 2014;33:43-50.
18. Bogstrand ST, Normann PT, Rossow I, Larsen M, Morland J, Ekeberg O. Prevalence of alcohol and other substances of abuse among injured patients in a Norwegian emergency department. Drug Alcohol Depend 2011;117:132-138.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
20. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139.
21. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the stage of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-736.
22. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol 2012;24:646-655.
23. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiological data. Am J Epidemiol 2009;170:244-256.
24. Andersen PK, Perme MP. Pseudo-observations in survival analysis. Stat Methods Med Res 2010;19:71-99.
25. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. Stata J 2010;10:408-422.
26. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;388:b2393.
27. Yuan YC. Proceedings of the twenty-fifth annual SAS Users Group International Conference: Paper 267;2000. Multiple imputation for missing data: concepts and new developmnents, pp. 1-11.
28. Petta S, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 2012;55:1317-1323.
29. Razavi H, Waked I, Sarrazin C, Myers RP, Iilman R, Calinas F, et al. The present and the future burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21(Suppl 1):34-59.
30. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012;55:1344-1355.
31. Innes H, Goldberg D, Dillon J, Hutchinson S. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public-health outcomes do we value most? Gut 2014 Nov 6. pii: gutjnl-2014-308166. doi: 10.1136/gutjnl-2014-308166. [Epub ahead of print].
32. Couzigou P. Virus C cure as a motivator for strong lifestyle change? Clin Gastroenterol Hepatol 2012;10:326; author reply, 326-327.
33. Sedgwick P. The Hawthorne effect. BMJ 2012;344:d8262.
34. Hepatitis Trust. Personal stories. Available at: http://www.hepctrust.org.uk/Living+with+Hep+C/Personal+Stories/Prison+story+2; http://www.hepctrust.org.uk/Living+with+Hep+C/Personal+Stories/Prison+ Story+1; http://www.hepctrust.org.uk/Living+with+Hep+C/Personal+Stories/Colins+story. Accessed May 2014.
35. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005;23:5814-5830.
36. O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res 2005;40:1620-1639.